©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Mar 24, 2025; 16(3): 101251
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.101251
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.101251
Safety and effectiveness of induction chemoimmunotherapy followed by definitive radiotherapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma
Zhuo-Jun Wei, Lin Wang, Rui-Qi Wang, Yu Wang, Huan Chen, Hong-Lian Ma, Yu-Jin Xu, Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China
Zhuo-Jun Wei, School of Medicine, Shaoxing University, Shaoxing 312000, Zhejiang Province, China
Author contributions: Wei ZJ generated conception, designed the study, and analyzed data; Xu YJ contributed to administrative support; Wei ZJ, Wang L, Wang RQ, Wang Y, Chen H, Ma HL, and Xu YJ provided study materials, collected the data, and wrote the manuscript; and all authors read and approved the final version.
Supported by Natural Science Foundation of Zhejiang Province, China, No. LGF21H160005; and Zhejiang Medical and Health Science and Technology Project, China, No. 2024KY049.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Zhejiang Cancer Hospital [Approval No. IRB-2024-223 (IIT)].
Informed consent statement: This research is a retrospective study. Patients were not required to provide informed consent for this study because the analysis used anonymous clinical data that were obtained after patient had agreed to treatment with written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Corresponding author: Yu-Jin Xu, PhD, Professor, Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, No.1 East Banshan Road, Gongshu District, Hangzhou 310022, Zhejiang Province, China. xuyj@zjcc.org.cn
Received: September 9, 2024
Revised: December 1, 2024
Accepted: December 25, 2024
Published online: March 24, 2025
Processing time: 134 Days and 4.9 Hours
Revised: December 1, 2024
Accepted: December 25, 2024
Published online: March 24, 2025
Processing time: 134 Days and 4.9 Hours
Core Tip
Core Tip: This study highlighted the safety and effectiveness of combining induction chemotherapy with programmed cell death 1/programmed cell death ligand 1 inhibitors followed by definitive radiotherapy or chemoradiotherapy, for locally advanced unresectable esophageal squamous cell carcinoma. It identified induction therapy effectiveness and maintenance immunotherapy as key prognostic factors, emphasizing the need for further validation through prospective trials.